Compounds that inhibits MCL-1 protein


Ontology type: sgo:Patent     


Patent Info

DATE

2022-01-18T00:00

AUTHORS

HARRINGTON PAUL E , ASHTON KATE , BROWN SEAN P , KALLER MATTHEW R , KOHN TODD J , LANMAN BRIAN ALAN , LI KEXUE , LI YUNXIAO , LOW JONATHAN D , MINATTI ANA ELENA , PICKRELL ALEXANDER J , STEC MARKIAN M , TAYGERLY JOSHUA

ABSTRACT

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. More... »

Related SciGraph Publications

  • 2008-12. BCL-2 family antagonists for cancer therapy in NATURE REVIEWS DRUG DISCOVERY
  • 2008-12-16. Mcl-1 is a potential therapeutic target in multiple types of cancer in CELLULAR AND MOLECULAR LIFE SCIENCES
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0305", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "name": "HARRINGTON PAUL E", 
            "type": "Person"
          }, 
          {
            "name": "ASHTON KATE", 
            "type": "Person"
          }, 
          {
            "name": "BROWN SEAN P", 
            "type": "Person"
          }, 
          {
            "name": "KALLER MATTHEW R", 
            "type": "Person"
          }, 
          {
            "name": "KOHN TODD J", 
            "type": "Person"
          }, 
          {
            "name": "LANMAN BRIAN ALAN", 
            "type": "Person"
          }, 
          {
            "name": "LI KEXUE", 
            "type": "Person"
          }, 
          {
            "name": "LI YUNXIAO", 
            "type": "Person"
          }, 
          {
            "name": "LOW JONATHAN D", 
            "type": "Person"
          }, 
          {
            "name": "MINATTI ANA ELENA", 
            "type": "Person"
          }, 
          {
            "name": "PICKRELL ALEXANDER J", 
            "type": "Person"
          }, 
          {
            "name": "STEC MARKIAN M", 
            "type": "Person"
          }, 
          {
            "name": "TAYGERLY JOSHUA", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nrd2658", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030857223", 
              "https://doi.org/10.1038/nrd2658"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00018-008-8637-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023498818", 
              "https://doi.org/10.1007/s00018-008-8637-6"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2022-01-18T00:00", 
        "description": "

    Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

    \n

    \"embedded
    \nor a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.\n

    ", "endDate": "2038-06-20", "id": "sg:patent.US-11224601-B1", "name": "Compounds that inhibits MCL-1 protein", "recipient": [ { "id": "http://www.grid.ac/institutes/grid.417886.4", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-11224601-B1" ], "sdDataset": "patents", "sdDatePublished": "2022-10-01T07:04", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/patent/patent_52.jsonl", "type": "Patent" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-11224601-B1'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-11224601-B1'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-11224601-B1'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-11224601-B1'


     

    This table displays all metadata directly associated to this object as RDF triples.

    82 TRIPLES      15 PREDICATES      18 URIs      9 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:patent.US-11224601-B1 schema:about anzsrc-for:03
    2 anzsrc-for:0305
    3 schema:author Ne6fb823991ef4235bd0978423e2df05f
    4 schema:citation sg:pub.10.1007/s00018-008-8637-6
    5 sg:pub.10.1038/nrd2658
    6 schema:datePublished 2022-01-18T00:00
    7 schema:description <p id="p-0001" num="0000">Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,</p> <p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="44.45mm" wi="69.93mm" file="US11224601-20220118-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif" orientation="portrait" inline="no"/><attachments><attachment idref="CHEM-US-00001" attachment-type="cdx" file="US11224601-20220118-C00001.CDX"/><attachment idref="CHEM-US-00001" attachment-type="mol" file="US11224601-20220118-C00001.MOL"/></attachments></chemistry><br/> or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. </p>
    8 schema:endDate 2038-06-20
    9 schema:name Compounds that inhibits MCL-1 protein
    10 schema:recipient grid-institutes:grid.417886.4
    11 schema:sameAs https://app.dimensions.ai/details/patent/US-11224601-B1
    12 schema:sdDatePublished 2022-10-01T07:04
    13 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    14 schema:sdPublisher Ne1698f9e9c6a46e7ace6a1e5af97ae6f
    15 sgo:license sg:explorer/license/
    16 sgo:sdDataset patents
    17 rdf:type sgo:Patent
    18 N190e139e62054a8593ae5f2a382c7e3f rdf:first N1bf6fc3624664763a8b8df2792afc2c4
    19 rdf:rest Nb0cd2ce1647446ffb1b6e85531f90095
    20 N1bf6fc3624664763a8b8df2792afc2c4 schema:name BROWN SEAN P
    21 rdf:type schema:Person
    22 N3f974af7883540e7ba943ec1c45a4761 schema:name STEC MARKIAN M
    23 rdf:type schema:Person
    24 N455f618133074a4a96c453928727c9a1 schema:name LI KEXUE
    25 rdf:type schema:Person
    26 N4914b21681c54eba9d4514f9bd044c06 rdf:first Nbe60f83a568247dcb892e9a5a3c70a54
    27 rdf:rest Naa4279d148694aea82c135cc3b9d5fc4
    28 N51f5c49f74c0464aa7ec322b73b067b5 schema:name PICKRELL ALEXANDER J
    29 rdf:type schema:Person
    30 N56c4e75b4db84927b0d20c87e05d9c99 schema:name MINATTI ANA ELENA
    31 rdf:type schema:Person
    32 N5bd1c85f6ccd4561a6f6953cdee4a371 schema:name LANMAN BRIAN ALAN
    33 rdf:type schema:Person
    34 N7e027d0f1e6e403f933c6dfff162dcec rdf:first N56c4e75b4db84927b0d20c87e05d9c99
    35 rdf:rest Nf0fabb8842cc4e87b1cbcaafe778789f
    36 N8afe2271f57040b1906ae474f1cb5a56 rdf:first Nae02005802c1414883f32c6bf3f8b5fb
    37 rdf:rest N190e139e62054a8593ae5f2a382c7e3f
    38 N92d1aa9f4a464868ba0444769b58f95a schema:name LOW JONATHAN D
    39 rdf:type schema:Person
    40 N98635cbd01cf4a609b5c278e24d7cd47 rdf:first Nac176182ad65414f8f8c3c1ac70d3417
    41 rdf:rest N991c65616b4342dab8fd992aac5eaad5
    42 N991c65616b4342dab8fd992aac5eaad5 rdf:first N5bd1c85f6ccd4561a6f6953cdee4a371
    43 rdf:rest Na65c2c23b51c4a8dbe345cc3385f5f5c
    44 Na1e1e087bcf3482295cbea7135d73d10 schema:name TAYGERLY JOSHUA
    45 rdf:type schema:Person
    46 Na52e656867a247eb91b5987478bf679b schema:name KALLER MATTHEW R
    47 rdf:type schema:Person
    48 Na65c2c23b51c4a8dbe345cc3385f5f5c rdf:first N455f618133074a4a96c453928727c9a1
    49 rdf:rest N4914b21681c54eba9d4514f9bd044c06
    50 Naa4279d148694aea82c135cc3b9d5fc4 rdf:first N92d1aa9f4a464868ba0444769b58f95a
    51 rdf:rest N7e027d0f1e6e403f933c6dfff162dcec
    52 Nac176182ad65414f8f8c3c1ac70d3417 schema:name KOHN TODD J
    53 rdf:type schema:Person
    54 Nae02005802c1414883f32c6bf3f8b5fb schema:name ASHTON KATE
    55 rdf:type schema:Person
    56 Nb0cd2ce1647446ffb1b6e85531f90095 rdf:first Na52e656867a247eb91b5987478bf679b
    57 rdf:rest N98635cbd01cf4a609b5c278e24d7cd47
    58 Nbe60f83a568247dcb892e9a5a3c70a54 schema:name LI YUNXIAO
    59 rdf:type schema:Person
    60 Nc0af4214d10c42858ee1cdf60b3a46a4 schema:name HARRINGTON PAUL E
    61 rdf:type schema:Person
    62 Nc9ecd9f1a603415f825cf830bcad01f0 rdf:first N3f974af7883540e7ba943ec1c45a4761
    63 rdf:rest Nd46a6830d90d497c832a038f84f4d665
    64 Nd46a6830d90d497c832a038f84f4d665 rdf:first Na1e1e087bcf3482295cbea7135d73d10
    65 rdf:rest rdf:nil
    66 Ne1698f9e9c6a46e7ace6a1e5af97ae6f schema:name Springer Nature - SN SciGraph project
    67 rdf:type schema:Organization
    68 Ne6fb823991ef4235bd0978423e2df05f rdf:first Nc0af4214d10c42858ee1cdf60b3a46a4
    69 rdf:rest N8afe2271f57040b1906ae474f1cb5a56
    70 Nf0fabb8842cc4e87b1cbcaafe778789f rdf:first N51f5c49f74c0464aa7ec322b73b067b5
    71 rdf:rest Nc9ecd9f1a603415f825cf830bcad01f0
    72 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
    73 rdf:type schema:DefinedTerm
    74 anzsrc-for:0305 schema:inDefinedTermSet anzsrc-for:
    75 rdf:type schema:DefinedTerm
    76 sg:pub.10.1007/s00018-008-8637-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023498818
    77 https://doi.org/10.1007/s00018-008-8637-6
    78 rdf:type schema:CreativeWork
    79 sg:pub.10.1038/nrd2658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030857223
    80 https://doi.org/10.1038/nrd2658
    81 rdf:type schema:CreativeWork
    82 grid-institutes:grid.417886.4 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...